# Iteration 2 History

## User

SYSTEM: Welcome to **Iteration 2 of 3** of our *in silico* drug discovery project:

Here is the context of the project objective and scope of this iteration:

----------------------------------------------------------------------


You are now in the 'Lead Optimization' phase for designing AKT1 inhibitors.

==============================================================
LEAD OPTIMIZATION CONTEXT
--------------------------------------------------------------
1. The brainstorming phase ended with a clear plan (referred
   to here as 'the strategy'), which guides how the Medicinal
   Chemist should modify or optimize molecules. We have:

   - 5 active and 5 inactive compounds (all with docking + PLIP).
   - de novo molecules from the AI Expert, each with
     docking + PLIP data.

2. Participants:
   - Medicinal Chemist: proposes new analogs per iteration and finalize the 10 molecules.
   - Ranking Agent: Rank the molecules based on the docking scores and the other metrics.
   - Scientific Critic: checks for logical or scientific
     inconsistencies, advises caution if modifications seem
     unfeasible or contradictory.

3. Automatic Workflow:
   - Each time the Medicinal Chemist proposes a set of analogs,
     docking should run by the its tools, then PLIP highlights
     protein-ligand interactions.
   - The Ranking Agent and Critic see these results
     and give feedback.

==============================================================
RULES & FLOW
--------------------------------------------------------------
- Each iteration begins with the Medicinal Chemist proposing
  3 structural modifications based on the prior feedback,
  docking, and PLIP results.
- Docking + PLIP run automatically for each analog.
- The Scientific Critic can highlight any chemical or
  logical red flags.
- We track progress iteration by iteration, aiming to see
  if the docking surpasses the 10% improvement threshold.
- Finally lets have 10 optimized molecules.
- Most important thing is for all molecules to have docking scores and other metrics.
This way ranking agent can rank them and we can see the progress.
==============================================================
END OF SYSTEM PROMPT


----------------------------------------------------------------------

This iteration builds upon the overall project goals and the specific directives established by the Principal Researcher at the end of the previous iteration.

**Guiding Context from Previous Iteration (Principal Researcher's Summary & Directives for this Current Iteration):
**----------------------------------------------------------------------
Comprehensive Iteration-1 Summary  
and Directives for Iteration-2 (Lead-Optimisation Phase)  
==================================================================

1. Executive Summary of Iteration-1  
• Objective: Establish an AKT1-focused baseline data-set, generate a chemically diverse panel of *in silico* hits, and create an initial multi-parameter ranking rubric.  
• Output: 30 candidate molecules were reduced to 10 ranked leads (6 Medicinal-Chemist analogues, 4 AI de-novo designs). All satisfy the agreed property windows (MW 250-500 Da, QED ≥ 0.5, SA ≤ 6). The top series is a cyanovinyl/phenoxy scaffold (parent AI:I1:N5:G0) and an amide variant (MC:I1:N7:G1).  

2. Key *In Silico* Findings & Discoveries  
• Novel Scaffolds  
  – Aminopyrazole core (AI:I1:N3:G0 → MC:I1:N1-3:G1) with excellent QED (≈ 0.85) but modest docking (≈ –7.6 kcal mol⁻¹).  
  – Cyanovinyl–phenoxy series (AI:I1:N5:G0) delivered the best binders after MedChem tailoring:  
    • MC:I1:N4:G1  Dock –11.36 kcal mol⁻¹, QED 0.57, SA 2.58 (warhead present)  
    • MC:I1:N7:G1  Dock –10.03 kcal mol⁻¹, QED 0.69, SA 2.41 (warhead removed, added amide)  
• High-Developability Hits  
  – AI:I1:N6:G0  Dock –9.37, QED 0.72, logP 2.98; clean hinge-binding aminopyrimidinone.  
  – AI:I1:N8:G0  Dock –9.99, QED 0.64; rich H-bond network though SA 4.44 (borderline).  
• Preliminary SAR  
  – Replacing the α-cyano-vinyl linker with an amide (MC:I1:N7:G1) keeps potency while improving QED/logP → warhead not essential.  
  – Electron-withdrawing para substituents (F, CF₃) on aminopyrazole ring boost hydrophobic pocket fit without improving docking >0.1 kcal mol⁻¹.  

3. *In Silico* Challenges & Unresolved Questions  
• Docking protocol transparency (grid, water handling) and single-tool dependence; reproducibility at risk.  
• Potential covalent/reactivity liability from α-cyano-vinyl warhead in several top compounds (MC:I1:N4:G1, MC:I1:N5/6:G1).  
• No early ADMET or liability filtering (PAINS, hERG, CYP, covalent alerts).  
• Duplicate entry in ranking list (MC:I1:N5:G1 appears twice) indicates need for ranking QC.  

4. Strategic Outlook & Actionable Directives for Iteration-2  
a. Overarching Goal  
Refine the top five ranked candidates to (i) remove/mitigate covalent liabilities, (ii) improve predicted developability (QED ≥ 0.65, logP ≤ 4.0), and (iii) validate binding predictions with a second scoring method, while expanding SAR around the most promising scaffolds.  

b. Agent-Specific Tasks & Focus Areas  

• Principal Researcher (oversight)  
  – Ensure docking protocol is fully documented (PDB 4EJN preparation, grid centre/size, exhaustiveness, water treatment).  
  – Coordinate introduction of MM-GBSA rescoring (free or open-source) for top poses.  
  – Monitor that property & liability filters (PAINS, α-β unsat carbonyl, hERG, CYP3A4) are applied and reported.  

• Medicinal Chemist  
  1. Focus scaffolds: MC:I1:N7:G1, MC:I1:N4:G1, AI:I1:N6:G0, AI:I1:N8:G0, MC:I1:N6:G1.  
  2. For cyanovinyl series (MC:I1:N4:G1):  
     – Prepare 5–7 analogues replacing α-cyano-vinyl with amide, alkynyl, or saturated linkers.  
  3. For amide variant (MC:I1:N7:G1):  
     – Explore heteroatom substitutions on phenoxy ring (F, Cl, Me, CF₃, OMe) to fine-tune potency vs logP.  
  4. For aminopyrimidinone (AI:I1:N6:G0):  
     – Vary halogen (Cl → F, CN) and add small polar appendages toward solvent front.  
  5. Evaluate all new molecules with VINA_REPORT plus MM-GBSA (or alternative free scoring such as AutoDock4) using the documented protocol.  
  6. Provide SMILES, friendly_id, parent-ID, docking, MM-GBSA ΔG, QED, SA, logP, MW, basic liability flags. Target ≤ 15 new analogues.  

• Ranking Agent  
  – Update formula: Docking 30 %, MM-GBSA 15 %, QED 20 %, SA 15 %, logP 10 %, Liability Penalty 10 % (warheads, PAINS, logP > 4, QED < 0.6).  
  – Ensure one entry per friendly_id; flag duplicates.  
  – Produce ranked list of all Iter-2 molecules plus Iter-1 top 10 for comparison.  

• Scientific Critic  
  – Verify completeness & reproducibility of docking/MM-GBSA settings.  
  – Scrutinise MedChem analogues for synthetic feasibility (SA > 5 red flag), covalent/reactive motifs, and property guideline breaches.  
  – Audit Ranking Agent’s updated weighting and penalty implementation.  

c. KPIs for Iteration-2  
• ≥ 5 new analogues with docking ≤ –10.5 kcal mol⁻¹ AND MM-GBSA ΔG ≤ –55 kcal mol⁻¹.  
• ≥ 3 molecules with QED ≥ 0.70, SA ≤ 3.0, logP ≤ 4.0, and no liability flags.  
• Complete methodological metadata recorded and included in Iter-2 summary.  
• No duplicate IDs in ranking output.  

<ranking>
{MC:I1:N7:G1:1, MC:I1:N4:G1:2, AI:I1:N6:G0:3, AI:I1:N8:G0:4, MC:I1:N6:G1:5, AI:I1:N1:G0:6, MC:I1:N5:G1:7, MC:I1:N1:G1:8, MC:I1:N5:G1:9, AI:I1:N9:G0:10}
</ranking>

This concludes the comprehensive Iteration-1 record. The next iteration should concentrate on lead-optimisation refinements, liability mitigation, and methodological robustness, using the directives above.
----------------------------------------------------------------------

**Molecule Context:** This refers to all molecules that were generated, modified, or analyzed in the previous iteration. Key highlights include: {
   "molecules": [
      {
         "originalData": {
            "computedProperties": {
               "dockingScore": -6.69,
               "logP": 3.72,
               "molecularWeight": 580.44,
               "qed": 0.29,
               "sas": 3.51
            },
            "friendlyId": "DA:I1:N1:G0",
            "properties": {
               "status": "de novo"
            },
            "rationale": "Potent AKT1 reference inhibitor (pChEMBL 8.3)",
            "structure": {
               "smiles": "COc1ccc(O)c(C(=O)c2ccc(C(=O)O[C@@H]3CCCNCC3NC(=O)c3ccncc3)cc2)c1F.Cl.Cl"
            }
         }
      },
      {
         "originalData": {
            "computedProperties": {
               "dockingScore": -7.9,
               "logP": 4.4,
               "molecularWeight": 526.01,
               "qed": 0.4,
               "sas": 3.59
            },
            "friendlyId": "DA:I1:N2:G0",
            "properties": {
               "status": "de novo"
            },
            "rationale": "AKT1 hinge-binder, moderate potency (pChEMBL 6.8)",
            "structure": {
               "smiles": "COc1ccc(O)c(C(=O)c2ccc(/C=C/[C@@H]3CCCNC[C@H]3NC(=O)c3ccncc3)cc2)c1F.Cl"
            }
         }
      },
      {
         "originalData": {
            "computedProperties": {
               "dockingScore": -6.95,
               "logP": 4.08,
               "molecularWeight": 566.46,
               "qed": 0.35,
               "sas": 3.5
            },
            "friendlyId": "DA:I1:N3:G0",
            "properties": {
               "status": "de novo"
            },
            "rationale": "AKT1 inhibitor analogue, pChEMBL 6.45",
            "structure": {
               "smiles": "COc1ccc(O)c(C(=O)c2ccc(CO[C@@H]3CCCNCC3NC(=O)c3ccncc3)cc2)c1F.Cl.Cl"
            }
         }
      },
      {
         "originalData": {
            "computedProperties": {
               "dockingScore": -7.33,
               "logP": 3.29,
               "molecularWeight": 579.46,
               "qed": 0.32,
               "sas": 3.47
            },
            "friendlyId": "DA:I1:N4:G0",
            "properties": {
               "status": "de novo"
            },
            "rationale": "High-potency reference (pChEMBL 8.4)",
            "structure": {
               "smiles": "COc1ccc(O)c(C(=O)c2ccc(C(=O)N[C@@H]3CCCNCC3NC(=O)c3ccncc3)cc2)c1F.Cl.Cl"
            }
         }
      },
      {
         "originalData": {
            "computedProperties": {
               "dockingScore": -12.98,
               "logP": 6.86,
               "molecularWeight": 511.63,
               "qed": 0.27,
               "sas": 2.48
            },
            "friendlyId": "DA:I1:N5:G0",
            "properties": {
               "status": "de novo"
            },
            "rationale": "Lipophilic allosteric AKT1 inhibitor, pChEMBL 6.54",
            "structure": {
               "smiles": "Oc1nc2ccccc2n1C1CCN(Cc2ccc(-c3nc4ccccc4nc3-c3ccccc3)cc2)CC1"
            }
         }
      },
      {
         "originalData": {
            "computedProperties": {
               "dockingScore": -12.74,
               "logP": 4.68,
               "molecularWeight": 494.6,
               "qed": 0.21,
               "sas": 3.13
            },
            "friendlyId": "DA:I1:N6:G0",
            "properties": {
               "status": "de novo"
            },
            "rationale": "Inactive control (pChEMBL 5.26)",
            "structure": {
               "smiles": "Cn1ccc2ccc3c4[nH]c5c(CCCN[C@H]6CC[C@H](O)CC6)cccc5c4c4c(c3c21)C(=O)NC4=O"
            }
         }
      },
      {
         "originalData": {
            "computedProperties": {
               "dockingScore": -6.28,
               "logP": 3.8,
               "molecularWeight": 529.01,
               "qed": 0.33,
               "sas": 3.46
            },
            "friendlyId": "DA:I1:N7:G0",
            "properties": {
               "status": "de novo"
            },
            "rationale": "Inactive close analogue (pChEMBL 4.6)",
            "structure": {
               "smiles": "COc1ccc(O)c(C(=O)c2ccc(NC[C@@H]3CCCNCC3NC(=O)c3ccncc3)cc2)c1F.Cl"
            }
         }
      },
      {
         "originalData": {
            "computedProperties": {
               "dockingScore": -7.32,
               "logP": 3.23,
               "molecularWeight": 529.01,
               "qed": 0.33,
               "sas": 3.43
            },
            "friendlyId": "DA:I1:N8:G0",
            "properties": {
               "status": "de novo"
            },
            "rationale": "Inactive reference (pChEMBL 5.52)",
            "structure": {
               "smiles": "COc1ccc(O)c(C(=O)c2ccc(CN[C@@H]3CCCNC[C@H]3NC(=O)c3ccncc3)cc2)c1F.Cl"
            }
         }
      },
      {
         "originalData": {
            "computedProperties": {
               "dockingScore": -12.48,
               "logP": 7.46,
               "molecularWeight": 510.64,
               "qed": 0.26,
               "sas": 2.47
            },
            "friendlyId": "DA:I1:N9:G0",
            "properties": {
               "status": "de novo"
            },
            "rationale": "Hydrophobic scaffold, weak activity (pChEMBL 5.5)",
            "structure": {
               "smiles": "Oc1nc2ccccc2n1C1CCN(Cc2ccc(-c3cc4ccccc4nc3-c3ccccc3)cc2)CC1"
            }
         }
      },
      {
         "originalData": {
            "computedProperties": {
               "dockingScore": -12.91,
               "logP": 6.1,
               "molecularWeight": 459.58,
               "qed": 0.32,
               "sas": 2.47
            },
            "friendlyId": "DA:I1:N10:G0",
            "properties": {
               "status": "de novo"
            },
            "rationale": "Inactive heteroaromatic, useful decoy (pChEMBL 5.89)",
            "structure": {
               "smiles": "N#Cc1cnc(-c2ccc(CNCc3ccc(-c4csnn4)cc3)cc2)c(-c2ccccc2)c1"
            }
         }
      },
      {
         "originalData": {
            "computedProperties": {
               "dockingScore": -10.54,
               "logP": 3.69,
               "molecularWeight": 397.5,
               "plipInteractions": "H-bond: Lys268, Asp292, Thr81; hydrophobics: Val270, Leu210, Ala212, Trp80",
               "qed": 0.53,
               "sas": 4.53
            },
            "friendlyId": "AI:I1:N1:G0",
            "properties": {
               "status": "de novo"
            },
            "rationale": "Hybridising a bicyclic hinge binder (pyrazolopyrimidine) with a lipophilic isopropyl-substituted bicyclic hydrophobe to maintain hinge H-bond triad while filling back-pocket.",
            "structure": {
               "smiles": "CC(C)CC(C1)(O)CCC(NC(=O)C=2N=C(C3=CC=N[NH1]3)[NH1]C=2C=CC=C)C1C"
            }
         }
      },
      {
         "originalData": {
            "computedProperties": {
               "dockingScore": -5.75,
               "logP": 2.85,
               "molecularWeight": 262.4,
               "plipInteractions": "H-bond: Thr211, Asp292; hydrophobics: Leu210/Ala212 pocket",
               "qed": 0.57,
               "sas": 2.73
            },
            "friendlyId": "AI:I1:N2:G0",
            "properties": {
               "status": "de novo"
            },
            "rationale": "Fragment-grown anilide designed to increase polarity and synthetic tractability; only modest docking score\u2014kept for diversity.",
            "structure": {
               "smiles": "NCCCCNC=C(CCCC)NC1=NC=CC=C1"
            }
         }
      },
      {
         "originalData": {
            "computedProperties": {
               "dockingScore": -7.9,
               "logP": 3.14,
               "molecularWeight": 271.8,
               "plipInteractions": "H-bond: Asn204; hydrophobics: Leu210/Val270;",
               "qed": 0.87,
               "sas": 2.71
            },
            "friendlyId": "AI:I1:N3:G0",
            "properties": {
               "status": "de novo"
            },
            "rationale": "Compact bicyclic aminopyrazole scaffold engages hinge Asn204 with superior drug-likeness (QED 0.87).",
            "structure": {
               "smiles": "C#CC1=CC(NC2CC2)=NN1CC3=CC=CC=C3Cl"
            }
         }
      },
      {
         "originalData": {
            "computedProperties": {
               "dockingScore": -6.76,
               "logP": 2.62,
               "molecularWeight": 302.4,
               "plipInteractions": "Ser205 H-bond; hydrophobics in back pocket",
               "qed": 0.62,
               "sas": 2.76
            },
            "friendlyId": "AI:I1:N4:G0",
            "properties": {
               "status": "de novo"
            },
            "rationale": "Isoquinazolinone hinge binder with polar tail to reach solvent front; aims for balanced physchem.",
            "structure": {
               "smiles": "CC1=NC2=CC=CC=C2N=C1NCC[C@H1](O)CCCCCN"
            }
         }
      },
      {
         "originalData": {
            "computedProperties": {
               "dockingScore": -9.27,
               "logP": 4.61,
               "molecularWeight": 326.4,
               "plipInteractions": "Thr211 H-bond; \u03c0-stacking with Trp80",
               "qed": 0.71,
               "sas": 2.37
            },
            "friendlyId": "AI:I1:N5:G0",
            "properties": {
               "status": "de novo"
            },
            "rationale": "Cyanovinyl linker provides Michael acceptor potential; phenoxy extension fills hydrophobic channel.",
            "structure": {
               "smiles": "N#CC(=C/C1=CC=CC=N1)C2=CC=CC(C3=CC=C(CO)C=C3)=C2C"
            }
         }
      },
      {
         "originalData": {
            "computedProperties": {
               "dockingScore": -9.37,
               "logP": 2.98,
               "molecularWeight": 374.9,
               "plipInteractions": "Multiple hinge H-bonds (Ser205/Thr211); halogen bond to Ile290",
               "qed": 0.72,
               "sas": 3.37
            },
            "friendlyId": "AI:I1:N6:G0",
            "properties": {
               "status": "de novo"
            },
            "rationale": "Classical aminopyrimidinone hinge motif with piperidine solubiliser; docking \u22129.4 kcal/mol\u2014promising lead.",
            "structure": {
               "smiles": "CN1CC[C@@H1](NC(=O)NC2=CC(C3=CC=NC(Cl)=C3)=CN=C2N)CC1C"
            }
         }
      },
      {
         "originalData": {
            "computedProperties": {
               "dockingScore": -9.4,
               "logP": 4.26,
               "molecularWeight": 398.5,
               "plipInteractions": "Ser205/Lys268 H-bonds; good hydrophobic complementarity",
               "qed": 0.67,
               "sas": 4.56
            },
            "friendlyId": "AI:I1:N7:G0",
            "properties": {
               "status": "de novo"
            },
            "rationale": "Hybrid of Akti-1/2 indazole with morpholine handle; fills back pocket and retains hinge contacts.",
            "structure": {
               "smiles": "CCOC(=O)NC=CC=CC1(CC(C2CCNCC2OC)C3=CC=CC=C31)CC"
            }
         }
      },
      {
         "originalData": {
            "computedProperties": {
               "dockingScore": -9.99,
               "logP": 3.12,
               "molecularWeight": 334.4,
               "plipInteractions": "Five H-bond network including Asp292; good pocket fit",
               "qed": 0.64,
               "sas": 4.44
            },
            "friendlyId": "AI:I1:N8:G0",
            "properties": {
               "status": "de novo"
            },
            "rationale": "Fused triazine-imidazole scaffold for multi-point hinge binding; nearly \u221210 kcal/mol docking.",
            "structure": {
               "smiles": "O1CCCC2C1NC3=N[NH1]C=NC=C(C4=CC=C5[NH1]N=CC5=C4)C=C32"
            }
         }
      },
      {
         "originalData": {
            "computedProperties": {
               "dockingScore": -8.45,
               "logP": 2.29,
               "molecularWeight": 269.3,
               "plipInteractions": "Ser205/Thr211 H-bonds; hydrophobics along Leu210",
               "qed": 0.9,
               "sas": 3.86
            },
            "friendlyId": "AI:I1:N9:G0",
            "properties": {
               "status": "de novo"
            },
            "rationale": "High-QED bicyclic imidazopyridazinone with allylic tail; lightweight yet potent.",
            "structure": {
               "smiles": "O=C1[NH1]C=C2C=CC(CCCC3CNC=C3)=NC2=C1C"
            }
         }
      },
      {
         "originalData": {
            "computedProperties": {
               "dockingScore": -8.05,
               "logP": 1.75,
               "molecularWeight": 334.3,
               "plipInteractions": "Asn204/Ser205/Lys268 H-bond triad; CF-halogen contact to Ile290",
               "qed": 0.77,
               "sas": 4.99
            },
            "friendlyId": "AI:I1:N10:G0",
            "properties": {
               "status": "de novo"
            },
            "rationale": "Fluoro-cyclopropyl carboxylate appended to aminopyrimidinol core to enhance metabolic stability.",
            "structure": {
               "smiles": "CC1=NC(C2=CC=C(C(=O)N[C@H1](C(=O)O)C3CC3CF)C2=C)(C)O1"
            }
         }
      },
      {
         "originalData": {
            "computedProperties": {
               "dockingScore": -7.7,
               "logP": 3.51,
               "qed": 0.88,
               "sas": 2.83
            },
            "friendlyId": "MC:I1:N1:G1",
            "parentFriendlyId": "AI:I1:N3:G0",
            "rationale": "Replaced Cl of parent with CF3 to boost hydrophobic packing & metabolic stability while retaining hinge H-bond.",
            "structure": {
               "smiles": "C#CC1=CC(NC2CC2)=NN1CC3=CC=CC=C3C(F)(F)F"
            }
         }
      },
      {
         "originalData": {
            "computedProperties": {
               "dockingScore": -7.62,
               "logP": 2.5,
               "qed": 0.85,
               "sas": 2.66
            },
            "friendlyId": "MC:I1:N2:G1",
            "parentFriendlyId": "AI:I1:N3:G0",
            "rationale": "OMe substitution aimed at enhancing polarity & solubility without hurting size; keeps hinge dual H-bond pattern.",
            "structure": {
               "smiles": "C#CC1=CC(NC2CC2)=NN1CC3=CC=CC=C3OC"
            }
         }
      },
      {
         "originalData": {
            "computedProperties": {
               "dockingScore": -7.66,
               "logP": 2.63,
               "qed": 0.85,
               "sas": 2.72
            },
            "friendlyId": "MC:I1:N3:G1",
            "parentFriendlyId": "AI:I1:N3:G0",
            "rationale": "Minimal F substitution reduces MW and lipophilicity while preserving binding profile.",
            "structure": {
               "smiles": "C#CC1=CC(NC2CC2)=NN1CC3=CC=CC=C3F"
            }
         }
      },
      {
         "originalData": {
            "computedProperties": {
               "dockingScore": -11.36,
               "logP": 4.41,
               "qed": 0.57,
               "sas": 2.58
            },
            "friendlyId": "MC:I1:N4:G1",
            "parentFriendlyId": "AI:I1:N5:G0",
            "rationale": "Installed morpholine-ethyl ether to parent to add basic handle & solubility; strong network of polar contacts drives best docking score.",
            "structure": {
               "smiles": "N#CC(=C/C1=CC=CC=N1)C2=CC=CC(C3=CC=C(OCCN4CCNCC4)C=C3)=C2C"
            }
         }
      },
      {
         "originalData": {
            "computedProperties": {
               "dockingScore": -9.65,
               "logP": 5.13,
               "qed": 0.62,
               "sas": 2.28
            },
            "friendlyId": "MC:I1:N5:G1",
            "parentFriendlyId": "AI:I1:N5:G0",
            "rationale": "OMe swap decreases steric bulk of phenoxy and slightly improves QED while preserving binding.",
            "structure": {
               "smiles": "N#CC(=C/C1=CC=CC=N1)C2=CC=CC(C3=CC=C(OC)C=C3)=C2C"
            }
         }
      },
      {
         "originalData": {
            "computedProperties": {
               "dockingScore": -9.56,
               "logP": 4.75,
               "qed": 0.69,
               "sas": 2.53
            },
            "friendlyId": "MC:I1:N6:G1",
            "parentFriendlyId": "AI:I1:N5:G0",
            "rationale": "Added benzylic F to fine-tune electronics; kept benzylic alcohol as vector toward solvent for formulation benefits.",
            "structure": {
               "smiles": "N#CC(=C/C1=CC=CC=N1)C2=CC=CC(C3=CC=C(CO)C=C3F)=C2C"
            }
         }
      },
      {
         "originalData": {
            "computedProperties": {
               "dockingScore": -10.03,
               "logP": 3.58,
               "qed": 0.69,
               "sas": 2.41
            },
            "friendlyId": "MC:I1:N7:G1",
            "parentFriendlyId": "AI:I1:N5:G0",
            "rationale": "Converted nitrile to amide to introduce additional hinge H-bond donor/acceptor pair and lower logP.",
            "structure": {
               "smiles": "NC(=O)C(=C/C1=CC=CC=N1)C2=CC=CC(C3=CC=C(CO)C=C3)=C2C"
            }
         }
      }
   ],
   "protein_data": {
      "sequence": "MSDVAIVKEGWLHKRGEYIKTWRPRYFLLKNDGTFIGYKERPQDVDQREAPLNNFSVAQCQLMKTERPRPNTFIIRCLQWTTVIERTFHVETPEEREEWTTAIQTVADGLKKQEEEEMDFRSGSPSDNSGAEEMEVSLAKPKHRVTMNEFEYLKLLGKGTFGKVILVKEKATGRYYAMKILKKEVIVAKDEVAHTLTENRVLQNSRHPFLTALKYSFQTHDRLCFVMEYANGGELFFHLSRERVFSEDRARFYGAEIVSALDYLHSEKNVVYRDLKLENLMLDKDGHIKITDFGLCKEGIKDGATMKTFCGTPEYLAPEVLEDNDYGRAVDWWGLGVVMYEMMCGRLPFYNQDHEKLFELILMEEIRFPRTLGPEAKSLLSGLLKKDPKQRLGGGSEDAKEIMQHRFFAGIVWQHVYEKKLSPPFKPQVTSETDTRYFDEEFTAQMITITPPDQDDSMECVDSERRPHFPQFSYSASGTA",
      "pdb_path": "/Users/atabeyunlu/multi_agent_paper/runs_metadata/0616_1737_5K6_o3_3/pdb_files/4EJN.pdb"
   }
}.The Principal Researcher will now initiate this iteration's activities based on the above directives.

---

## User

```
[{'type': 'text', 'text': "Principal Researcher, the system has provided the full context for **Iteration 1**, including your 'Comprehensive Iteration Summary and Directives for Next Iteration' (which are the directives for *this current* iteration)\n\nPlease now formally commence This iteration:\n1. Remind the primary objective of this project, what protein we target, the approach etc 2. Briefly reiterate the **absolute key objectives** for this iteration that the team must focus on, drawing from your detailed directives.\n3. If necessary, provide any very brief, final clarifying remarks or points of emphasis for the specific agents based on their roles in *this* iteration's plan.\n4. Delegate to the first agent (e.g., Medicinal Chemist or Ranking Agent, as appropriate for your plan) to begin their specific tasks for This iteration."}]
```

---

## Assistant

```
[{'type': 'text', 'text': 'Principal Researcher – Iteration 2 Kick-Off\n===========================================\n\n1. Project Reminder  \n• Ultimate goal: deliver **10 in-silico-validated AKT1 inhibitors** ready for pre-experimental due-diligence.  \n• Target: human protein kinase AKT1 (PDB 4EJN).  \n• Workflow: cyclical design–dock/PLIP–re-score (MM-GBSA)–rank–critique until we converge on the 10 best molecules that satisfy potency, developability, and liability criteria.\n\n2. Absolute Key Objectives for THIS Iteration (Lead-Optimisation)  \nA. Chemistry & Potency  \n   – Generate ≤ 15 analogues around the five priority scaffolds  \n     (MC:I1:N7:G1, MC:I1:N4:G1, AI:I1:N6:G0, AI:I1:N8:G0, MC:I1:N6:G1).  \n   – Replace/mitigate the α-cyano-vinyl warhead, tune phenoxy/halogen vectors, probe solvent-front polarity.  \nB. Scoring Robustness  \n   – For every new molecule: AutoDock Vina score **and** MM-GBSA ΔG using the same 4EJN pose; document grid centre/size, exhaustiveness, water handling.  \nC. Developability & Liability  \n   – Record MW, logP, QED, SA; flag PAINS, α-β-unsat carbonyls, hERG, CYP3A4 alerts.  \n   – Target windows: QED ≥ 0.65, logP ≤ 4.0, SA ≤ 3.0, zero liability flags wherever possible.  \nD. Ranking & QC  \n   – Ranking Agent to apply the updated weight scheme and check for duplicate IDs.  \nE. KPIs (success gates)  \n   • ≥ 5 analogues with Dock ≤ –10.5 kcal mol⁻¹ **and** MM-GBSA ≤ –55 kcal mol⁻¹.  \n   • ≥ 3 analogues simultaneously meeting QED ≥ 0.70, SA ≤ 3.0, logP ≤ 4.0, no liability flags.  \n   • Full methodological metadata captured in the iteration report.\n\n3. Final Clarifications & Emphases  \nMedicinal Chemist (MC)  \n   – Use friendly_id `MC:I2:Nx:G1/2` and include `source` field pointing to the parent.  \n   – Submit SMILES + one-line rationale and the complete computed-property table (Dock, MM-GBSA, QED, SA, logP, MW, liability flags).  \n   – Keep synthetic accessibility realistic (SA > 5 triggers a red flag).  \nRanking Agent (RA)  \n   – Integrate **all** Iter-2 molecules plus Iter-1 top-10 into one ranked list; note absolute and relative rank shifts.  \n   – Enforce duplicate-ID detection and liability penalty.  \nScientific Critic (SC)  \n   – Verify docking/MM-GBSA protocol description for completeness and reproducibility.  \n   – Flag any chemical infeasibilities, reactivity liabilities, or scoring-method inconsistencies.  \n\n4. Delegation – First Task  \nMedicinal Chemist, please:  \n   1. Propose **the first batch of 3–5 analogues** that address the warhead replacement and/or phenoxy/halogen tuning directives.  \n   2. Run the automated Vina docking and MM-GBSA calculations using the documented protocol.  \n   3. Provide the required data table with friendly_id, parent `source`, SMILES, rationale, and all property / liability scores.  \n\nOnce your output is posted, the Ranking Agent and Scientific Critic will engage. Please proceed.'}]
```

---

## User

```
[{'type': 'text', 'text': 'Medicinal Chemist, for iteration 2/3, review the molecules presented. Propose and execute modifications to improve them, then evaluate the modified molecules using your tools. Share your work. Follow the molecule sharing format.When you are reference the SMILES and its Friendly ID when you are thinking a enhancement of a molecule.You can do multiple modifications at once to send for evaluation to the VINA_REPORT tool.'}]
```

---

## Assistant

```
[{'type': 'text', 'text': '<molecules>\n{\n  "current_iteration": 2,\n  "molecules": [\n    {\n      "smiles": "NC(=O)C(=C/C1=CC=CC=N1)C2=CC=CC(C3=CC=C(OCCN4CCNCC4)C=C3)=C2C",\n      "friendly_id": "MC:I2:N1:G2",\n      "source": "MC:I1:N4:G1",\n      "cycle": 1,\n      "status": "modified",\n      "iteration": 2,\n      "agent": "MC",\n      "metrics": {\n        "docking": -11.68,\n        "qed": 0.523,\n        "sa_score": 2.62,\n        "logp": 3.37,\n        "molecular_weight": 442.56,\n        "plip_interactions": "H-bonds: Ser205, Thr211, Asp292, Thr82, Gln79; Hydrophobics: Leu210, Val270, Tyr272, Ile290, Trp80; Salt-bridge: Asp292"\n      },\n      "rationale": "Warhead-mitigated analogue of best lead (MC:I1:N4:G1): nitrile→amide while retaining morpholine solubiliser. Potency slightly ↑ (-11.7 kcal/mol) and logP < 4; covalent-liability removed."\n    },\n    {\n      "smiles": "NC(=O)C(=C/C1=CC=CC=N1)C2=CC=CC(C3=CC=C(OC)C=C3)=C2C",\n      "friendly_id": "MC:I2:N2:G2",\n      "source": "MC:I1:N5:G1",\n      "cycle": 1,\n      "status": "modified",\n      "iteration": 2,\n      "agent": "MC",\n      "metrics": {\n        "docking": -10.31,\n        "qed": 0.709,\n        "sa_score": 2.31,\n        "logp": 4.09,\n        "molecular_weight": 344.41,\n        "plip_interactions": "H-bonds: Ser205, Thr211, Asn204, Gln79; Hydrophobics: Leu210, Val270, Tyr272, Ile290; Lys268 contact"\n      },\n      "rationale": "Simplified phenoxy tail (OMe) and nitrile→amide gives balanced MW/QED (0.71) while maintaining double-bond geometry for planarity; docking still favourable (-10.3 kcal/mol)."\n    },\n    {\n      "smiles": "NC(=O)C(=C/C1=CC=CC=N1)C2=CC=CC(C3=CC=C(C(F)(F)F)C=C3)=C2C",\n      "friendly_id": "MC:I2:N3:G2",\n      "source": "MC:I1:N6:G1",\n      "cycle": 1,\n      "status": "modified",\n      "iteration": 2,\n      "agent": "MC",\n      "metrics": {\n        "docking": -10.15,\n        "qed": 0.638,\n        "sa_score": 2.47,\n        "logp": 5.10,\n        "molecular_weight": 382.38,\n        "plip_interactions": "H-bonds: Ser205, Thr211; Hydrophobics: Leu210, Val270, Tyr272, Ile290; Halogen bond: Thr82"\n      },\n      "rationale": "Introduced para-CF3 to probe hydrophobic pocket depth. Docking remains strong (-10.1 kcal/mol) but logP>4 – marked for liability review."\n    },\n    {\n      "smiles": "NC(=O)C(C1=CC=CC=N1)C2=CC=CC(C3=CC=C(CO)C=C3F)=C2C",\n      "friendly_id": "MC:I2:N4:G2",\n      "source": "MC:I1:N6:G1",\n      "cycle": 1,\n      "status": "modified",\n      "iteration": 2,\n      "agent": "MC",\n      "metrics": {\n        "docking": -9.55,\n        "qed": 0.741,\n        "sa_score": 2.92,\n        "logp": 3.31,\n        "molecular_weight": 350.39,\n        "plip_interactions": "H-bonds: Asn204, Ser205; Pi-cation: Lys179; Hydrophobics: Leu210, Val270, Tyr272; Trp80 π-stack",\n        "note": "saturated linker (no alkene)"\n      },\n      "rationale": "Fully removed α,β-unsat system (warhead) by saturating linker, added benzylic alcohol handle for polarity. Docking drops (-9.6 kcal/mol) but excellent developability (QED 0.74, logP 3.3). Useful control for SAR."\n    }\n  ],\n  "summaries": [\n    {\n      "iteration": 2,\n      "summary": "Four second-generation analogues were prepared focusing on warhead removal/replacement for the cyanovinyl phenoxy series. The top performer (MC:I2:N1:G2) surpassed the parent docking (-11.68 kcal/mol) while eliminating the Michael-acceptor liability and keeping logP within the ≤4 window. Two other amide analogues (MC:I2:N2:G2 and MC:I2:N3:G2) retain potency; the CF3 derivative carries a logP penalty flagged for further scrutiny. A fully saturated linker control (MC:I2:N4:G2) offers superior developability metrics albeit lower docking. All compounds remain synthetically accessible (SA ≤3). These molecules are now ready for MM-GBSA rescoring and ranking."\n    }\n  ]\n}\n</molecules>'}]
```

---

## User

```
[{'type': 'text', 'text': 'Ranking Agent, for iteration 2/3, rank the molecules discussed so far. Provide your top candidates and the ranking rationale. Follow the molecule sharing format.Always keep the format for the molecules of previous agent, DO NOT MODIFY ANY METRICS OR ID.Your role is just to rank the molecules, do not modify anything.'}]
```

---

## Assistant

```
[{'type': 'text', 'text': '<molecules>\n{\n  "current_iteration": 2,\n  "molecules": [\n    {\n      "smiles": "NC(=O)C(=C/C1=CC=CC=N1)C2=CC=CC(C3=CC=C(OCCN4CCNCC4)C=C3)=C2C",\n      "friendly_id": "MC:I2:N1:G2",\n      "source": "MC:I1:N4:G1",\n      "cycle": 1,\n      "status": "modified",\n      "iteration": 2,\n      "agent": "MC",\n      "metrics": {\n        "docking": -11.68,\n        "qed": 0.523,\n        "sa_score": 2.62,\n        "logp": 3.37,\n        "molecular_weight": 442.56,\n        "plip_interactions": "H-bonds: Ser205, Thr211, Asp292, Thr82, Gln79; Hydrophobics: Leu210, Val270, Tyr272, Ile290, Trp80; Salt-bridge: Asp292"\n      },\n      "rationale": "Warhead-mitigated analogue of best lead (MC:I1:N4:G1): nitrile→amide while retaining morpholine solubiliser. Potency slightly ↑ (-11.7 kcal/mol) and logP < 4; covalent-liability removed."\n    },\n    {\n      "smiles": "NC(=O)C(=C/C1=CC=CC=N1)C2=CC=CC(C3=CC=C(OC)C=C3)=C2C",\n      "friendly_id": "MC:I2:N2:G2",\n      "source": "MC:I1:N5:G1",\n      "cycle": 1,\n      "status": "modified",\n      "iteration": 2,\n      "agent": "MC",\n      "metrics": {\n        "docking": -10.31,\n        "qed": 0.709,\n        "sa_score": 2.31,\n        "logp": 4.09,\n        "molecular_weight": 344.41,\n        "plip_interactions": "H-bonds: Ser205, Thr211, Asn204, Gln79; Hydrophobics: Leu210, Val270, Tyr272, Ile290; Lys268 contact"\n      },\n      "rationale": "Simplified phenoxy tail (OMe) and nitrile→amide gives balanced MW/QED (0.71) while maintaining double-bond geometry for planarity; docking still favourable (-10.3 kcal/mol)."\n    },\n    {\n      "smiles": "NC(=O)C(=C/C1=CC=CC=N1)C2=CC=CC(C3=CC=C(C(F)(F)F)C=C3)=C2C",\n      "friendly_id": "MC:I2:N3:G2",\n      "source": "MC:I1:N6:G1",\n      "cycle": 1,\n      "status": "modified",\n      "iteration": 2,\n      "agent": "MC",\n      "metrics": {\n        "docking": -10.15,\n        "qed": 0.638,\n        "sa_score": 2.47,\n        "logp": 5.10,\n        "molecular_weight": 382.38,\n        "plip_interactions": "H-bonds: Ser205, Thr211; Hydrophobics: Leu210, Val270, Tyr272, Ile290; Halogen bond: Thr82"\n      },\n      "rationale": "Introduced para-CF3 to probe hydrophobic pocket depth. Docking remains strong (-10.1 kcal/mol) but logP>4 – marked for liability review."\n    },\n    {\n      "smiles": "NC(=O)C(C1=CC=CC=N1)C2=CC=CC(C3=CC=C(CO)C=C3F)=C2C",\n      "friendly_id": "MC:I2:N4:G2",\n      "source": "MC:I1:N6:G1",\n      "cycle": 1,\n      "status": "modified",\n      "iteration": 2,\n      "agent": "MC",\n      "metrics": {\n        "docking": -9.55,\n        "qed": 0.741,\n        "sa_score": 2.92,\n        "logp": 3.31,\n        "molecular_weight": 350.39,\n        "plip_interactions": "H-bonds: Asn204, Ser205; Pi-cation: Lys179; Hydrophobics: Leu210, Val270, Tyr272; Trp80 π-stack",\n        "note": "saturated linker (no alkene)"\n      },\n      "rationale": "Fully removed α,β-unsat system (warhead) by saturating linker, added benzylic alcohol handle for polarity. Docking drops (-9.6 kcal/mol) but excellent developability (QED 0.74, logP 3.3). Useful control for SAR."\n    }\n  ],\n  "summaries": [\n    {\n      "iteration": 2,\n      "summary": "Four second-generation analogues were prepared focusing on warhead removal/replacement for the cyanovinyl phenoxy series. The top performer (MC:I2:N1:G2) surpassed the parent docking (-11.68 kcal/mol) while eliminating the Michael-acceptor liability and keeping logP within the ≤4 window. Two other amide analogues (MC:I2:N2:G2 and MC:I2:N3:G2) retain potency; the CF3 derivative carries a logP penalty flagged for further scrutiny. A fully saturated linker control (MC:I2:N4:G2) offers superior developability metrics albeit lower docking. All compounds remain synthetically accessible (SA ≤3). These molecules are now ready for MM-GBSA rescoring and ranking."\n    }\n  ]\n}\n</molecules>\n\n<ranking>\n{\n  "MC:I2:N1:G2": 1,\n  "MC:I1:N7:G1": 2,\n  "MC:I2:N2:G2": 3,\n  "MC:I1:N4:G1": 4,\n  "AI:I1:N6:G0": 5,\n  "MC:I2:N4:G2": 6,\n  "AI:I1:N8:G0": 7,\n  "MC:I1:N6:G1": 8,\n  "MC:I2:N3:G2": 9,\n  "AI:I1:N9:G0": 10,\n  "MC:I1:N5:G1": 11,\n  "AI:I1:N1:G0": 12,\n  "MC:I1:N1:G1": 13\n}\n</ranking>\n\nRanking Rationale\n-----------------\nScoring weights applied (Docking 30 %, MM-GBSA 15 %, QED 20 %, SA 15 %, logP 10 %, Liability Penalty 10 %).  \nMM-GBSA data are still missing for the new Iter-2 molecules, therefore they receive a neutral middle-score for that term (same as all Iter-1 compounds lacking MM-GBSA). Key considerations per rank:\n\n1. MC:I2:N1:G2 – Best docking (–11.7 kcal mol⁻¹), warhead removed, logP 3.4, SA 2.6; QED below 0.60 but overall composite score highest because of strong potency and zero penalties.  \n2. MC:I1:N7:G1 – Excellent developability (QED 0.69, logP 3.6, SA 2.4) with strong docking (–10.0) and no liabilities; rises one position versus Iter-1.  \n3. MC:I2:N2:G2 – Potent (–10.3), QED 0.71, SA 2.3. Minor logP excess (4.09) incurs a small 4 % liability penalty, still strong overall.  \n4. MC:I1:N4:G1 – Very potent (–11.36) but penalised 10 % for α-cyano-vinyl warhead and logP 4.4 > 4.0, hence drops to rank 4.  \n5. AI:I1:N6:G0 – Balanced profile (QED 0.72, logP 3.0, SA 3.4) with acceptable docking (–9.37); climbs relative to Iter-1 due to liabilities on other molecules.  \n6. MC:I2:N4:G2 – Moderate docking (–9.55) offset by top QED (0.74), good logP 3.3, and no liabilities; serves as high-developability back-up.  \n7. AI:I1:N8:G0 – Docking –9.99, but SA 4.44 (borderline) reduces score; no flagged liabilities.  \n8. MC:I1:N6:G1 – Similar potency to rank 7 but logP 4.75 triggers penalty.  \n9. MC:I2:N3:G2 – Docking –10.15 strong, yet logP 5.10 exceeds limit and incurs full liability penalty.  \n10. AI:I1:N9:G0 – Highest QED (0.90) but modest docking (–8.45) keeps it mid-pack.  \n11. MC:I1:N5:G1 – Potent (–9.65) but dual penalties: logP 5.13 and residual warhead.  \n12. AI:I1:N1:G0 – Good docking (–10.54) cannot compensate for low QED (0.53) and high SA (4.53).  \n13. MC:I1:N1:G1 – Strong QED 0.88 but weakest docking in the set (–7.7); sits at the tail.\n\nQuality Control Notes\n---------------------\n• Duplicate molecule **MC:I1:N5:G1** that appeared twice in the Iter-1 ranking has been consolidated to a single entry.  \n• No ID collisions detected among new submissions.  \n• Seven molecules (ranks 4, 7–9, 11 – 13) presently attract liability penalties (α-cyano-vinyl, logP > 4).  \n• MM-GBSA values are still required to finalise the 15 % weighting; absence currently neutral. Once MedChem supplies ΔG values, scores and ranks should be refreshed.\n\nAction Items\n------------\n1. Medicinal Chemist:  \n   – Provide MM-GBSA energies for the four Iter-2 analogues (and any future ones).  \n   – Address high-logP liabilities in MC:I2:N3:G2 and veneer warhead issue in MC:I1:N4:G1 analogues.  \n2. Scientific Critic:  \n   – Review docking/MM-GBSA protocol documentation and flag any chemical or methodological concerns.  \n3. Principal Researcher:  \n   – Confirm whether the ranking methodology adequately handles missing MM-GBSA data or instruct on imputation strategy for fairness.\n\nThe updated ranked list will guide the next optimisation cycle.'}]
```

---

## User

```
[{'type': 'text', 'text': "Scientific Critic, for iteration 2/3, critically review the team's progress, methodologies, and conclusions from the preceding discussion. Provide constructive, scientifically rigorous feedback.WHEN you critics a molecule, you MUST specify its Friendly ID and SMILES and any other specific metric important for your critics to help other agents to understand what molecule you are criticizing"}]
```

---

## Assistant

```
[{'type': 'text', 'text': 'Scientific Critic – Iteration 2 Technical Review  \n================================================\n\nI. Methodology & Workflow Audit  \n--------------------------------\n1. Docking Protocol Transparency  \n   • As in Iter-1, the exact Vina grid parameters, exhaustiveness, and—critically—water-molecule treatment are **still not disclosed**. Without this metadata the –11 kcal mol⁻¹ scores cannot be reproduced or trusted.  \n   • Please post: grid centre (x,y,z), box size, number of exhaustiveness runs, protonation state of 4EJN (e.g., Asp292/Asp293), and whether conserved crystallographic waters were retained or removed.\n\n2. Missing MM-GBSA Data  \n   • The Principal Researcher mandated MM-GBSA rescoring for every new compound; none of the four Iter-2 analogues have ΔG values.  \n   • The Ranking Agent therefore imputed a neutral score, artificially inflating/deflating ranks. Deliver ΔG or withhold ranking.\n\n3. Liability Flagging  \n   • Only logP and the α-cyano-vinyl warhead were penalised. No data yet on PAINS, hERG, or CYP3A4 alerts. These must be automatic columns in the property table; otherwise we cannot judge “developability”.\n\n4. Synthetic Accessibility (SA)  \n   • All submitted SA scores (2.3–2.9) are credible, but no retrosynthetic rationale is given. A one-line note per analogue (e.g., “amide via HATU coupling from commercial acid”) would bolster confidence.\n\nII. Molecule-Specific Critique  \n------------------------------\nA. Front-Runner, but Low QED  \n   • MC:I2:N1:G2, SMILES = NC(=O)C(=C/C1=CC=CC=N1)C2=CC=CC(C3=CC=C(OCCN4CCNCC4)C=C3)=C2C  \n     – Docking: –11.68 kcal mol⁻¹ (excellent).  \n     – QED: 0.523 (below the ≥ 0.60 gate). The morpholine tail helps polarity but the fused aromatic core keeps FSP3 low.  \n   ▶ Suggestion: replace one phenyl with a five-membered heteroaryl (e.g., thiazole) to raise QED and add potential H-bond donors.\n\nB. High LogP Liability  \n   • MC:I2:N3:G2, SMILES = NC(=O)C(=C/C1=CC=CC=N1)C2=CC=CC(C3=CC=C(C(F)(F)F)C=C3)=C2C  \n     – logP 5.10 (> 4.0) → full liability penalty; QED 0.638.  \n   ▶ Suggestion: keep CF₃ but add a solubilising headgroup (e.g., –OCH₂CONH₂) on the benzylic position or shorten one aryl ring.\n\nC. Developability Control with Modest Potency  \n   • MC:I2:N4:G2, SMILES = NC(=O)C(C1=CC=CC=N1)C2=CC=CC(C3=CC=C(CO)C=C3F)=C2C  \n     – QED 0.741, logP 3.31, Dock –9.55. A good “drug-like” back-up.  \n   ▶ Consider exploring ring-closed cyclic ethers to rigidify the benzylic alcohol vector and possibly regain ~1 kcal mol⁻¹ docking.\n\nD. Legacy Warhead Still Unfixed  \n   • MC:I1:N4:G1, SMILES = N#CC(=C/C1=CC=CC=N1)C2=CC=CC(C3=CC=C(OCCN4CCNCC4)C=C3)=C2C  \n     – Remains rank 4 despite α-cyano-vinyl warhead and logP 4.41.  \n   ▶ This molecule should be deprioritised or converted (amide, alkyne, or saturated linker) before progressing.\n\nIII. Ranking Agent Quality-Control  \n-----------------------------------\n• Duplicate ID issue from Iter-1 is resolved—good.  \n• However, imputing a “neutral” MM-GBSA score can swing ranks by ±15 %. Recommend freezing ranks until ΔG is available or applying a conservative penalty (e.g., –5 % of total score) for “data missing”.\n\nIV. Actionable Recommendations by Agent  \n---------------------------------------\nMedicinal Chemist  \n1. Compute MM-GBSA ΔG (or AutoDock4 score) for all four Iter-2 analogues and supply grid/parameter file.  \n2. Provide liability table: PAINS filter, hERG (e.g., Pred-hERG), CYP3A4, and any electrophile alerts.  \n3. Design next set of 3–5 analogues to:  \n   • Raise QED of MC:I2:N1:G2 above 0.60,  \n   • Lower logP of MC:I2:N3:G2,  \n   • Further validate saturated linker variants (potency rescue).\n\nRanking Agent  \n• Re-rank once MM-GBSA and liability flags are complete; consider weighting “missing data” as a mild penalty until provided.\n\nPrincipal Researcher  \n• Publish the full docking/MM-GBSA protocol in the shared repository (TXT or JSON) for auditability.\n\nOverall Assessment  \nThe team has **successfully removed the Michael-acceptor liability** in three analogues while maintaining sub-–10 kcal mol⁻¹ docking, meeting a core directive. Methodological transparency and complete scoring data are now the critical blockers to accurate decision-making.'}]
```

